COMPREHENSIVE REVIEW ON NUCLEAR FACTOR-ΚB (NF-ΚB) SIGNALING AND ITS ROLE IN AUTOIMMUNE DISEASES.
Main Article Content
Keywords
Nuclear factor-Kappa B (NF-kB), Signalling, Canonical, Non-canonical, Autoimmune diseases
Abstract
Nuclear factor-Kappa B (NF-kB) is an inactive transcription factor that became activated when translocate from cytoplasm to the nucleus, where it affects the expression of approximately 300 immunological, growth, and inflammatory genes. There are five members of the NF-kB family have been identified. There are two mechanisms for NF-kB activation: canonical and non-canonical signalling. NF-kB transcription factors are important regulators of both innate and adaptive immune responses, and abnormalities in NF-kB signalling lead to the development of immunological disorders. As a result of its activities during thymic selection, NF-kB is critical for maintaining immunological tolerance, both for negative selection of autoreactive T cells and for the selection and maintenance of Tregs. Rheumatoid arthritis, multiple sclerosis, thyroid illness, diabetes, asthma, systemic lupus erythematosus, and inflammatory bowel disease have all been associated to NF-kB. The goal of this review is to discuss about molecular mechanism of NF-kB and how it implicated in the pathogenesis of human diseases.
Downloads
References
1. Mamatha Serasanambati, Shanmuga Reddy Chilakapati. Function of Nuclear Factor kappa B (NF-kB) in human diseases-A Review. South Indian Journal of Biological Sciences, 2016; 2(4); 368-87. 2. Liu, T., Zhang, L., Joo, D. et al. NF-κB signaling in inflammation. Sig Transduct Target Ther 2, 17023 (2017). https://doi.org/10.1038/sigtrans.2017.23 3. Miraghazadeh B and Cook MC. Nuclear Factor-kappaB in Autoimmunity: Man and Mouse. Front. Immunol. 2018; 9: 613. https://doi.org/10.3389/fimmu.2018.00613 4. Philipp J. Jost and Jurgen Ruland. Aberrant NF-B signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood, 2007; 109 (7): 2700–7. https://doi.org/10.1182/blood-2006-07-025809 5. Hayden MS, Ghosh S. Signalling to NF-kappaB. Genes Dev. 2004; 18:2195–224. doi:10.1101/gad.1228704 6. Patel S., Santani D. Role of NF-kB in the pathogenesis of diabetes and its associated complications. Pharmacol. Rep. 2009; 61595–603. https://doi.org/10.1016/S1734-1140(09)70111-2 7. Janin Hofmann, Florian Mair, Melanie Greter, Marc Schmidt-Supprian and Burkhard Becher. NIK signalling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J. Exp. Med. 2011 Aug 29; 208(9): 1917–29. doi: 10.1084/jem.20110128 8. Sun SC, Chang JH, Jin J. Regulation of nuclear factor-κB in autoimmunity. Trends Immunol. 2013; 34(6): 282-9. doi: 10.1016/j.it.2013.01.004 9. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. Dec 2011; 12(12):1184-93. DOI:10.1038/ni.2135 10. Shimon Sakaguchi, Tomoyuki Yamaguchi, Takashi Nomura, Masahiro Ono. Regulatory T cells and immune tolerance. Cell, 30 May 2008; 133(5): 775–87. https://doi.org/10.1016/j.cell.2008.05.009 11. B. Singh, S. Read, C. Asseman, V. Malmstrom, C. Mottet, L.A. Stephens, R. Stepankova, H. Tlaskalova, F. Powrie. Control of intestinal inflammation by regulatory T cells Immunol. Rev., 2001; 182: 2190-200. 12. Schmitz, M., Krappmann, D. Controlling NF-κB activation in T cells by costimulatory receptors. Cell Death Differ 2006; 13: 834–42. doi:10.1038/sj.cdd.4401845 13. Jan Schulze-Luehrmann, Sankar Ghosh. Antigen-Receptor Signaling to Nuclear Factor κB. Immunity. November 2006; 25(5): 701-15. https://doi.org/10.1016/j.immuni.2006.10.010 14. Gilmore, T. Introduction to NF-κB: players, pathways, perspectives. Oncogene. Published: 30 October 2006; 25(51): 6680–4. 15. Felicity D. Herrington, Ruaidhri J. Carmody, and Carl S. Goodyear. Modulation of NF-κB signaling as a Therapeutic Target in Autoimmunity. Journal of Biomolecular Screening 2016, Vol. 21(3) 223–42. 16. Mingzhao Zhu and Yangxin Fu. The complicated role of NF-kB in T-cell selection. Cell Mol Immunol, published online 2010 Mar 1; 7: 89–93. doi: 10.1038/cmi.2009.112 17. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J. 2004 Aug 24; 382(Pt 2): 393-409. doi: 10.1042/BJ20040544 18. Chang M, Jin W, Chang JH, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011; 12(10): 1002-9. doi:10.1038/ni.2090 19. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-Gamma Is an Essential Regulatory Subunit of the IkappaB Kinase Complex. Nature, 1998; 395: 297–300. https://doi.org/10.1038/26261 20. Barnabei Laura, Laplantine Emmanuel, Mbongo William, Rieux-Laucat Frédéric, Weil Robert. NF-κB: At the Borders of Autoimmunity and Inflammation. Frontiers in Immunology. 2021 Aug 9; 12: 716469. doi: 10.3389/fimmu.2021.716469 21. Doffinger R, Smahi A, Bessia C, Geissmann F, Feinberg J, Durandy A, et al. X-Linked Anhidrotic Ectodermal Dysplasia With Immunodeficiency is Caused by Impaired NF-kappaB Signaling. Nat Genet, 2001 Mar; 27(3): 277-85. DOI:10.1038/85837 22. Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, et al. A Novel X-Linked Disorder of Immune Deficiency and Hypohidrotic Ectodermal Dysplasia Is Allelic to Incontinentia Pigmenti and Due to Mutations in IKK-gamma (NEMO). Am J Hum Genet, 2000 Dec; 67(6): 1555–62. doi: 10.1086/316914 23. Chen N-J, Chio IIC, Lin W-J, Duncan G, Chau H, Katz D, et al. Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors. Proc Natl Acad Sci U S A, Published online 2008 Aug 21; 105(34): 12429–34. 24. West A.P.et al. Recognition and signaling by toll-like receptors. Annu. Rev. Cell Dev. Biol. November 2006; 22: 409-37. 25. Kawai T, Akira S. Signaling of NF-kappaB by Toll-like Receptors. Trends Mol Med. November 1, 2017; 13(11): 460-9. doi:10.1016/j.molmed.2007.09.002 26. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science, 2000 Sep 29; 289(5488): 2350–4. 27. Jingjing Wang, Xinjie Wu, Mengyu Jiang, Guixiang Tai. Mechanism by which TRAF6 Participates in the Immune Regulation of Autoimmune Diseases and Cancer. BioMed Research International, Published online 2020 Nov 26; 2020: 4607197. doi: 10.1155/2020/4607197 28. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res. 2011; 21: 71-85. Published: 21 December 2010. 29. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009 Dec; 1(6): a001651. Doi: 10.1101/cshperspect.a001651 30. Sun S. C. The noncanonical NF-κB pathway. Immunological reviews, 2012 Mar; 246(1): 125–140. doi: 10.1111/j.1600-065X.2011.01088.x 31. Gutian Xiao, Edward W. Harhaj and Shao-Cong Sun. NF-kB-Inducing Kinase Regulates the Processing of NF-kB2 p100. Mol Cell, Feb 1, 2001; 7: 401–409. 32. Senftleben U., Cao Y., Xiao G., Greten F. R., Krahn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.-C., Karin M. Activation by IKKα of a second evolutionary conserved, NF-κB signaling pathway. Science. 2001; 293: 1495–9. 33. Roy E, Byrareddy SN, Reid SP. Role of MicroRNAs in Bone Pathology during Chikungunya Virus Infection. Viruses, Published online 2020 Oct 23; 12(11): 1207. doi: 10.3390/v12111207 34. Myrthe A. M. van Delft, Leonie F. A. Huitema and Sander W. Tas. The contribution of NF-kB signalling to immune regulation and tolerance. . European Journal of Clinical Investigation, 2015; 45(5): 529-39. https://doi.org/10.1111/eci.12430 35. Heino M, Peterson P, Sillanpaa N, Guerin S, Wu L, Anderson G, Scott HS, Antonarakis SE, Kudoh J, Shimizu N, Jenkinson EJ, Naquet P, and Krohn KJ. RNA and protein expression of the murine autoimmune regulator gene (Aire) in normal, RelB-deficient and in NOD mouse. Eur J Immunol, 25 August 2000; 30: 1884–93. https://doi.org/10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P 36. Li, Xinran & Xie, Jiaxin & Wang, Qingru & Cai, Huihua & Xie, Chuhai & Fu, Xiafei. miR-21 and Pellino-1 Expression Profiling in Autoimmune Premature Ovarian Insufficiency. Journal of Immunology Research. 2020 Apr 13; 2020: 3582648. 37. Matthew s.Hayden & Sankar Ghosh. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012 Feb 1; 26(3): 203–34. Doi: 10.1101/gad.183434.111 38. Fliegauf M, Bryant VL, Frede N, Slade C, Woon S-T, Lehnert K, et al. Haploinsufficiency of the NF-κB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet, 2015 Sep 3; 97(3): 389–403. doi: 10.1016/j.ajhg.2015.07.008 39. Vasanthakumar A, Liao Y, Teh P, Pascutti MF, Oja AE, Garnham AL, et al. The TNF receptor superfamily-NF-κB axis is critical to maintain effector regulatory T cells in lymphoid and non-lymphoid tissues. Cell Rep, September 19, 2017; 20(12): 2906–20. https://doi.org/10.1016/j.celrep.2017.08.068 40. Lee CE, Fulcher DA, Whittle B, Chand R, Fewings N, Field M, et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood, 2014 Nov 6; 124(19): 2964–72. doi: 10.1182/blood-2014-06-578542 41. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163–96. 42. Nejatbakhsh Samimi L, Farhadi E, Tahmasebi MN, Jamshidi A, Sharafat Vaziri A, Mahmoudi M. NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes. Auto Immun Highlights. Published: 8 Aug 2020; 11: 11. 43. Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. Published online 2001 Mar 26; 3(4): 200-6. Doi: 10.1186/ar300 44. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw. 1993; 4(1): 15-23. 45. Boniface K, Moynet D, Mossalayi MD. Role of Th17 cells in the pathogenesis of rheumatoid arthritis. World J Rheumatol 2013; 3(3): 25-31 [DOI: 10.5499/wjr.v3.i3.25] 46. Hwang S-Y, Kim J-Y, Kim K-W, Park M-K, Moon Y, Kim W-U, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB-and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004; 6: R120-28. 47. Mellado M, Martínez-Muñoz L, Cascio G, Lucas P, Pablos JL, Rodríguez-Frade JM. T cell Migration in Rheumatoid Arthritis. Front Immunol. 2015 Jul 27; 6: 384. doi: 10.3389/fimmu.2015.00384 48. Cildir G, Low KC, Tergaonkar V. Noncanonical NF-κB signaling in health and disease. Trends Mol Med. 2016; 22: 414–29. 49. Leibowitz SM, Yan J. NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications. Front Mol Neurosci. 2016 Sep 15; 9: 84. doi: 10.3389/fnmol.2016.00084 50. Yue Y, Stone S, Lin W. Role of nuclear factor κB in multiple sclerosis and experimental autoimmune encephalomyelitis. Neural Regen Res. 2018 Sep; 13(9): 1507–1515. doi: 10.4103/1673-5374.237109 51. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009 Jun; 9(6): 393–407. doi: 10.1038/nri2550 52. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015 Aug; 15(9). DOI:10.1038/nri3871 53. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006; 354: 942–55. 54. Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004; 103(11): 4222-31. https://doi.org/10.1182/blood-2003-11-4025 55. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med, May 2004; 199(7): 971-9. DOI:10.1084/jem.20031579 56. Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995; 95(6): 2711-9. 10.1172/JCI117973 57. Selmaj KW, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest, 1991 Mar; 87(3): 949-54. doi: 10.1172/JCI115102 58. Giuliani C, Bucci I, Napolitano G. The Role of the Transcription Factor Nuclear Factor-kappa B in Thyroid Autoimmunity and Cancer. Front Endocrinol (Lausanne). Aug 21 2018; 9: 471. doi: 10.3389/fendo.2018.00471 59. Pacifico F, Leonardi A. Role of NF-κB in thyroid cancer. Mol Cell Endocrinol. 2010; 321: 29–35. 60. Namba, Saenko & Yamashita. Nuclear Factor-κB in Thyroid Carcinogenesis and Progression: a Novel Therapeutic Target for Advanced Thyroid Cancer. Arq Bras Endocrinol Metab, July 2007; 51 (5). https://doi.org/10.1590/S0004-27302007000500023 61. Francesco Pacifico et al. Oncogenic and Anti-apoptotic Activity of NF-B in Human Thyroid Carcinomas. THE JOURNAL OF BIOLOGICAL CHEMISTRY, December 2004; 279(52): P54610-9. DOI: https://doi.org/10.1074/jbc.M403492200 62. Faria M, Domingues R, Paixão F, Bugalho MJ, Matos P, Silva AL. TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells. PLoS ONE, Published: February 12, 2020; 15(2): e0228794. https://doi.org/10.1371/journal.pone.0228794 63. Tavares C, Coelho MJ, Eloy C, et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Connect. 2018 Jan; 7(1):78-90. doi: 10.1530/EC-17-0302 64. Suryavanshi, Sachin v, yogesh a kulkarni. NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes. frontier in pharmacology, 2017; 8: 798. doi: 10.3389/fphar.2017.00798 65. Kira Meyerovich, Makiko Fukaya, Leticia F. Terra, Fernanda Ortis, Decio L. Eizirik & Alessandra K. Cardozo. The non-canonical NF-κB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro. Diabetologia, 2016 Mar; 59(3): 512-21. DOI: 10.1007/s00125-015-3817-z 66. Elizabeth Dale, Miriam Davis, Denise L. Faustman. A role for transcription factor NF-κB in autoimmunity: possible interactions of genes, sex, and the immune response. Advances in Physiology Education. 2006; 30: 152-8. https://doi.org/10.1152/advan.00065.2006 67. Gray CM, Remouchamps C, McCorkell KA, et al. Noncanonical NF-κB signalling is limited by classical NF-κB activity. Sci Signal, 2014 Feb 4; 7(311): ra13. doi: 10.1126/scisignal.2004557 68. Ortis F, Miani M, Colli ML, et al. Differential usage of NF-κB activating signals by IL-1β and TNF-α in pancreatic beta cells. FEBS Lett, 22 February 2012; 586(7): 984–9. https://doi.org/10.1016/j.febslet.2012.02.021 69. Kim JE, Lee MH, Nam DH, Song HK, Kang YS, et al. Celastrol, an NF-kB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice. PLoS ONE, Published online 2013 Apr 26; 8(4): e62068. doi: 10.1371/journal.pone.0062068 70. Guadalupe Rico-Rosillo, Gloria Bertha Vega-Robledo. The involvement of NF-κB Transcription factor in asthma. Rev Alergia Mex 2011; 58(2): 107-111. 71. Vikas Mishra, Jaspreet Banga, and Patricia Silveyra. Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets. Pharmacol Ther. 2018 January; 181: 169–82. doi: 10.1016/j.pharmthera.2017.08.011 72. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med, May 1997; 336(15): 1066-71. DOI:10.1056/NEJM199704103361506 73. Sheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in trans-repression of NF-kB by activated glucocorticoid receptors. Mol Cell Biol, Feb 1995; 15(2): 943-53. DOI: 10.1128/MCB.15.2.943 74. Hans D. Brightbill et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. 2018 Jan 12; 9(1): 179. DOI: 10.1038/s41467-017-02672-0 75. Pacheco GV et al. Expression of TLR-7, MyD88, NF-kB, and INF-α in B Lymphocytes of Mayan Women with Systemic Lupus Erythematosus in Mexico. Front. Immunol. 2016; 7: 22. doi: 10.3389/fimmu.2016.00022 76. Fang sun, Jian teng, Pengfei yu, Wenshuang li, Jing chang and Honglei xu. Involvement of TWEAK and the NF κB signalling pathway in lupus nephritis. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018; 15: 2611-9. 77. Rakesh K. Mishra. Involvement of NF-κB Signalling Pathway in the Pathogenesis of Systemic Lupus Erythematosus. Nephrol Open J. 2016; 2(1): 9-13. http://dx.doi.org/10.17140/NPOJ-2-112 78. Wong HK, Kammer GM, Dennis G, and Tsokos GC. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol, 1999 Aug 1; 163(3): 1682–9. 79. Lewis MJ, Simon Vyse, Adrian M. Shields, Sebastian Boeltz, et al. UBE2L3 polymorphism amplifies NF-κB activation and promotes plasma cell development, linking linear ubiquitination to multiple autoimmune diseases. Am J Hum Genet. 2015 Feb 5; 96(2): 221-34. Doi: 10.1016/j.ajhg.2014.12.024 80. I. Atreya, R. Atreya, M. F. Neurath. NF-κB in inflammatory bowel disease. Journal of internal medicine, June 2008; 263(6): 591-6. https://doi.org/10.1111/j.1365-2796.2008.01953.x 81. Clara Abraham 1, Judy H Cho. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19; 361(21): 2066-78. DOI: 10.1056/NEJMra0804647 82. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol. 2005 Jun; 5(6): 435-45. DOI: 10.1038/nri1629
Article Sidebar
Published
Feb 28, 2023
Article Details
How to Cite
1.
Aditi H. Bariya 1*, Vinay C. Darji1, Nishkruti R. Mehta2, Divyakant A. Patel3, Purva S. Modi4
COMPREHENSIVE REVIEW ON NUCLEAR FACTOR-ΚB (NF-ΚB) SIGNALING AND ITS ROLE IN AUTOIMMUNE DISEASES.
. 2023 Feb. 13;94(1): 224-239. Available from: https://mattioli.1885journals.com/article/2023/224.html
Issue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.